CD274 and non-small cell lung carcinoma: However, advanced NSCLC patients, regardless of PD-L1 expression on TC, benefited from first-line combination therapy with platinum-based chemotherapy and pembrolizumab (KEYNOTE-189 and KEYNOTE-407 studies) (18–21).